News

Cornerstone Therapeutics has reported an increase in net revenues by 78% to $25m for the second quarter ended June 30, 2009, as compared to $14m for the second

The low-dose diet pill – Alli will be available over the counter in Taiwan. This makes the pill the first to be sold over the counter in Taiwan

Tolerx has reported changes to the protocol for its phase 3 clinical trial – DEFEND. The trial is testing the safety and efficacy of otelixizumab, a targeted T

Caraco Pharmaceutical has launched sumatriptan succinate tablets on behalf of Sun Pharmaceutical Industries, immediately following Sun Pharma’s recently received FDA approval for its Abbreviated New Drug Application (ANDA)

Endocyte has reported the results from phase II clinical study of EC145. The single arm phase II study evaluated the therapeutic agent, EC145 and the molecular imaging agent,

Ranbaxy has received final approval from FDA to manufacture and market Sumatriptan Succinate Tablets, 25mg (base) and 50mg (base). The Office of Generic Drugs, FDA, has determined Ranbaxy

Hospira has reported the US Food and Drug Administration’s approval and launch of oxaliplatin injection in the US. The medication is a generic version of Sanofi-Aventis’ Eloxatin. Hospira’s

Vion Pharmaceuticals has reported a net loss of $6.6m or $0.83 per share for the second quarter of 2009, a decrease when compared to a net loss of

A 96-week study results published in AIDS (the official journal of the International AIDS Society) has shown that Prezista (darunavir) was found to be non-inferior to lopinavir/RITONAVIR. The